Lilly Announces Final Exchange Ratio of 4.5121 for Elanco Exchange Offer Read more about Lilly Announces Final Exchange Ratio of 4.5121 for Elanco Exchange Offer
Lilly Receives FDA Priority Review Designation for Emgality® (galcanezumab-gnlm) Injection for the Preventive Treatment of Episodic Cluster Headache in Adults Read more about Lilly Receives FDA Priority Review Designation for Emgality® (galcanezumab-gnlm) Injection for the Preventive Treatment of Episodic Cluster Headache in Adults
Lilly to Present Data Demonstrating Continued Scientific Advancements in Broad Dermatology Portfolio at AAD Annual Meeting Read more about Lilly to Present Data Demonstrating Continued Scientific Advancements in Broad Dermatology Portfolio at AAD Annual Meeting
Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain Read more about Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain
Lilly Completes Acquisition of Loxo Oncology Read more about Lilly Completes Acquisition of Loxo Oncology
Lilly To Participate in Leerink Partners Global Healthcare Conference Read more about Lilly To Participate in Leerink Partners Global Healthcare Conference
Boehringer Ingelheim and Lilly announce the CAROLINA® cardiovascular outcome trial of Tradjenta® met its primary endpoint of non-inferiority compared with glimepiride Read more about Boehringer Ingelheim and Lilly announce the CAROLINA® cardiovascular outcome trial of Tradjenta® met its primary endpoint of non-inferiority compared with glimepiride
Lilly to Participate in Guggenheim Healthcare Talks Idea Forum Read more about Lilly to Participate in Guggenheim Healthcare Talks Idea Forum
Lilly Will Initiate Divestiture of its Remaining Interest in Elanco Animal Health Read more about Lilly Will Initiate Divestiture of its Remaining Interest in Elanco Animal Health
